Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $276K fell 63.9% year over year, behind the +8.7% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 0.8% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -63.9% toward the trailing-twelve-month pace of +8.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$276K+119.9% QoQ
Last fiscal yearDec 2025
-$1.1M-155.6% YoY
LTMMar 2026
-$1.59M+8.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.9%——
1 year-155.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.1M) USD
Year-over-year change
-155.6%

Accounts Payables vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 accounts payables of $1.59M is the 3rd largest of the 4 companies compared; the peer median is $1.9M.
  • Its year-over-year change of +8.7% is the highest of 4, against a peer median of -145.7%.
  • Accounts payables amounts to 1.1% of revenue for KPTI, versus a peer median of 67.4%.
KPTI Competitors Peer median
Accounts Payables for KPTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$6.08M -378.1%—67.4%
INMBINmune Bio, Inc.LTM Mar 2026$1.9M -7.3%+9.8%—
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$1.59M +8.7%—1.1%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$49.76K -145.7%——
Peer median (excluding KPTI) $1.9M-145.7%+9.8%67.4%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Depreciation & Amortization789K621K530K340K(114K)
Deferred Income Tax1.45M0000
Stock-Based Compensation29.78M35.4M21.71M18.43M14.05M
Change in Working Capital(23.19M)(19.99M)31.42M(302K)28.27M
Accounts Receivables(9.62M)(5.08M)20.12M(3.8M)4.59M
Inventory(1.46M)(118K)1.18M(1.7M)701K
Accounts Payables(2.85M)1.17M350K1.98M(1.1M)
Other Working Capital(9.26M)(15.96M)9.76M3.21M24.09M
Other Non-Cash Items8.14M(294K)(3.28M)(69.53M)78.46M
Operating Cash Flow(107.12M)(149.55M)(92.72M)(127.49M)(75.37M)
Capital Expenditures(5.71M)(118K)0(142K)0
Acquisitions (Net)5.5M104.26M000
Purchases of Investments(45.23M)(226.02M)(159.15M)(58.82M)0
Sales of Investments192.78M121.88M167.09M154.44M43.38M
Other Investing Activities(5.5M)(104.26M)000
Investing Cash Flow141.84M(104.26M)7.94M95.47M43.38M
Debt Repayment60M0083.3M20.54M
Common Stock Issued9.9M189.76M1.12M1.45M9.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.75M3.98M0(43.11M)0
Financing Cash Flow73.65M193.74M1.12M41.65M30.05M
Effect of Forex Changes(48K)(488K)(34K)(11K)20K
Net Change in Cash108.32M(60.56M)(83.69M)9.62M(1.92M)
Free Cash Flow(112.83M)(149.67M)(92.72M)(127.63M)(75.37M)

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.